KNSA Company Profile and Key Details

Q: Who are the executives of KNSA?

Mr. Michael R. Megna CPAChief Accounting Officer & Group Vice President of Fin.Ms. Madelyn ZeylikmanSVice President, Gen. Counsel & Sec.Ms. Mei JangSenior Vice President of Technical OperationsMr. Sanj K. PatelChief Executive Officer & ChairmanMr. Eben TessariSenior Vice President & Chief Operating OfficerRachel FrankAssociate Director of Investor RelationsMs. Melissa MannoSenior Vice President & Chief HR OfficerDr. John F. PaoliniSenior Vice President & Chief Medical OfficerMr. Chad MorinSVice President, Chief Compliance Officer & Head of QualityMr. Mark Ragosa C.F.A.Senior Vice President & Chief Financial Officer

NASDAQ : KNSA

Kiniksa Pharmaceuticals

$44.71

-0.27-0.60%

At Close 4:00 PM

BESG ScoreESG Rating

Profile Key Stats Analyst Ratings Ownership Ratios Financials Dividend & splits Sentiment Forecast

Price Chart

Stock Price Today

Kiniksa Pharmaceuticals, Ltd. (KNSA) stock declined over -0.60%, trading at $44.71 on NASDAQ, down from the previous close of $44.98. The stock opened at $45.00, fluctuating between $43.50 and $45.40 in the recent session.

Stock Snapshot

44.98

Prev. Close

3.28B

Market Cap

43.5

Day Low

99.36

P/E Ratio

0.45

EPS (TTM)

Cash Flow per Share

Open

73.29M

Number of Shares

45.4

Day High

95.61%

Free Float in %

0.01

Book Value

309.56K

Volume

Relevant Articles

SEC Fillings

Current Report (8-k)

Filing Date	Accepted Date

Annual Report (10-k)

Filing Date	Accepted Date

Stock Price History Chart

Date	Open	High	Low	Close	Volume
Feb 12, 2026	45.00	45.50	43.50	44.71	309.56K
Feb 11, 2026	44.44	44.98	43.11	44.98	338.65K
Feb 10, 2026	44.22	45.00	43.94	44.71	386.65K
Feb 09, 2026	43.15	44.43	42.00	44.35	375.78K
Feb 06, 2026	42.77	43.74	42.69	43.09	309.42K
Feb 05, 2026	43.41	44.34	41.98	42.58	323.34K
Feb 04, 2026	44.97	45.09	43.09	43.52	515.56K
Feb 03, 2026	44.37	45.50	44.26	44.96	435.68K
Feb 02, 2026	43.65	45.02	43.65	44.67	382.99K
Jan 30, 2026	44.02	44.56	43.18	43.92	987.04K
Jan 29, 2026	43.34	44.16	43.15	43.96	485.25K
Jan 28, 2026	45.00	45.00	42.99	43.28	698.5K
Jan 27, 2026	43.26	44.66	43.25	44.64	341.77K
Jan 26, 2026	42.09	43.40	41.50	43.20	617.77K
Jan 23, 2026	42.39	43.00	41.65	42.20	597.56K
Jan 22, 2026	41.83	42.75	41.22	42.44	542.69K
Jan 21, 2026	40.57	42.13	40.43	41.83	1.09M
Jan 20, 2026	38.79	41.04	38.40	41.03	516.77K
Jan 16, 2026	38.11	39.47	38.04	39.41	757.2K
Jan 15, 2026	39.56	39.74	37.02	37.92	1.01M

Contact Details

Hamilton, HM 11

Bermuda

https://www.kiniksa.com 781 439 9100

About Company

Kiniksa Pharmaceuticals, Ltd., a biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs worldwide. Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatment of recurrent pericarditis, which is an inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody inhibitor that completed Phase II clinical trials for the treatment of giant cell arteritis; Vixarelimab, a monoclonal antibody, which is in Phase 2a clinical trial for the treatment of prurigo nodularis, a chronic inflammatory skin condition; and KPL-404, a monoclonal antibody inhibitor of the CD40- CD154 interaction, a T-cell co-stimulatory signal critical for B-cell maturation, immunoglobulin class switching, and type 1 immune response. Kiniksa Pharmaceuticals, Ltd. was incorporated in 2015 and is based in Hamilton, Bermuda.

Stock Peers

ARGX

-1.01-0.12%

argenx SE$833.54 REGN

4.68+0.60%

Regeneron Pharmaceuticals, Inc.$783.65 UTHR

0.28+0.06%

United Therapeutics Corporation$476.13 MDGL

-7.21-1.50%

Madrigal Pharmaceuticals, Inc.$473.79 VRTX

3.78+0.82%

Vertex Pharmaceuticals Incorporated$465.02 PRAX

9.63+2.98%

Praxis Precision Medicines, Inc.$332.92 KRTX

0.09+0.03%

Karuna Therapeutics, Inc.$329.83 ALNY

-13.8-4.28%

Alnylam Pharmaceuticals, Inc.$308.48 KRYS

-2.39-0.88%

Krystal Biotech, Inc.$270.26 SGEN

-0.16-0.07%

Seagen Inc.$228.74

Company Overview

Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA) closed at $44.71 USD, losing -$0.27 (-0.60%) from the previous close of $44.98. The stock is currently within 5% of its 52-week high $18.25 and $45.50. With a market capitalization of about $3.28 billion, Kiniksa Pharmaceuticals, Ltd. is classified as a mid-cap and shows lower-than-market volatility (beta ~0.05). Key stats such as the average daily volume over the past year has been around 498.24 thousand shares, volume is running light vs its 52-week average. Headquartered in Hamilton, None, Kiniksa Pharmaceuticals, Ltd. operates in the Healthcare sector and the Biotechnology industry. Led by CEO Sanj K. Patel, the company employs approximately 315 people and listed since May 25, 2018. Kiniksa Pharmaceuticals, Ltd., a biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs worldwide.

Technical Performance

Short-term trend indicators are bearishly aligned (SMA20 3.81%, SMA50 6.16%, SMA200 26.52%). The stock’s 14-day RSI is 58.22 (neutral), while the ATR of 1.73 points to higher daily volatility. The stock remains hovering near 52-week lows, trading -1.74% below its high and over 144.92% above its low. Average 10-day trading volume of 375.29 thousand shares is below the 3-month average of 454.98 thousand, indicating normal recent market interest.

Valuation Metrics

Kiniksa Pharmaceuticals, Ltd. trades at a P/E ratio of 92.16, slightly above the S&P 500 average, with a price-to-sales ratio of 5.51 and a price-to-book ratio of 6.18 trading at moderately above to book value. The P/FCF stands at 32.4, also above market averages.

Dividend & Fair Value

Kiniksa Pharmaceuticals, Ltd. last paid a dividend of 0 per share, Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around -$4.53. This means the shares are trading below this model’s fair value.

Earnings & Analyst Outlook

Kiniksa Pharmaceuticals, Ltd. generated EPS of $0.45 over the past year. Five-year average earnings growth is 27.38%. The latest quarter delivered EPS of $0.23. The next quarter is forecast at $0.32. Next year's EPS is expected at -$146.48. Analyst sentiment is bullish. Analyst rating data shows there are 4 Strong Buy ratings, 6 Buy ratings, 0 Hold ratings, 0 Sell rating and 0 Strong Sell ratings. Price targets range from $60.00 to $40.00. The high target offers 34.2% upside. The low target suggests -10.53% downside. The mean target is $48.50. This offers 8.48% upside. Kiniksa Pharmaceuticals, Ltd. earnings surprise history is a mixed track record. The quarter that ended October 28, 2025, missed forecasts by -30.3%. The prior quarter beat by 27.78%. Over the last six quarters, Apple has recorded several small beats. These include -233.22% in July 23, 2024.

Shareholding & Insider Activity

Kiniksa Pharmaceuticals, Ltd. has 43.47 million shares outstanding. The public float is 33.55 million shares, elevated short interest at 6.06% of float. This equals 2.43 million shares. The short ratio is 3.63 days. Institutional investors hold 96.58% of the float. Insiders own 3.74%. Cormorant Asset Management, LP holds 900.44 thousand shares, Flynn James E has 333.33 thousand shares and BAKER BROS. ADVISORS LP has 299.40 thousand shares. Over the past six months, insider transactions show net selling. They sold 648.06 thousand shares across 27 transactions.

Financial & Profitability Overview

Over the trailing twelve months, Kiniksa Pharmaceuticals generated $270.26M in revenue, or $3.76 per share. Gross margin was 66.31%, operating margin -9.32%, and net profit margin 5.21%. Returns are modest, with ROA at 2.68% and ROE at 3.21%.
On valuation metrics, Kiniksa Pharmaceuticals trades at a P/E of 92.16, P/S of 5.51 and P/B of 6.18. The current ratio is 3.85 and quick ratio is 3.51. Operationally, the company’s inventory turnover is 6.82 and cash conversion cycle is 77.13 days. Debt-to-equity is 0.02, supported by a cash flow-to-debt ratio of 10.58.

Quarterly Financial Highlights

For the quarter ended Dec 31, 2023, Kiniksa Pharmaceuticals posted revenue of $270.26M, down slightly from $220.18M in the prior quarter. Gross profit was $179.22M (margin 66.31%). Operating income was - $25.20M (margin -9.3%). Net income was$14.08M (EPS $0.20).
The company ended the quarter with $206.37M in cash and short-term investments, a total debt of $12.26M, and net debt of - $95.70M. Total assets were $526.32M, with equity of $438.84M. Financials further reflected stability, with operating cash flow of $13.30M, free cash flow of $13.17M, and capital expenditures of - $130.00K.

Price Forecast & Outlook

Our AI price prediction model suggests that Kiniksa Pharmaceuticals, Ltd. stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected increase of 5.32%, with price expected at $47.09 by February 25, 2026, within a range of $45.69 to $48.46 3-Month Outlook: Projected rise of 31.98%, reaching $59.01 by May 12, 2026, with a range of $58.39 to $59.75. 1-Year Outlook: Projected gain of 22.48%, with price at $54.76 by February 11, 2027, within a range of $53.14 to $56.35.

Key Takeaways

Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA) shares are flat -0.53% year-to-date currently trading near 52-week highs band. Short-term momentum has been positive over the last quarter, despite recent volatility. Valuation shows Kiniksa Pharmaceuticals, Ltd. trading at a premium to the broader market with a P/E of 92.16. Analyst sentiment is bullish, with the majority of ratings in Outperform territory and a mean price target of $38.96, suggesting -12.86% downside. Our AI forecast model points to short-term strength (5.32% over two weeks), a medium-term rise (31.98% over three months), and a longer-term gain (22.48% over one year), with expected trading ranges indicating moderate volatility.

Frequently Asked Questions

What is the current Kiniksa Pharmaceuticals, Ltd. (KNSA) stock price?

Kiniksa Pharmaceuticals, Ltd. (NASDAQ: KNSA) stock price is $44.71 in the last trading session. During the trading session, KNSA stock reached the peak price of $45.40 while $43.50 was the lowest point it dropped to. The percentage change in KNSA stock occurred in the recent session was -0.6% while the dollar amount for the price change in KNSA stock was - $0.27.

KNSA's industry and sector of operation?

The NASDAQ listed KNSA is part of Biotechnology industry that operates in the broader Healthcare sector. Kiniksa Pharmaceuticals, Ltd. designs, manufactures, and markets smartphones, personal computers, tablets, wearables, and accessories worldwide.

Who are the executives of KNSA?

Mr. Michael R. Megna CPA
Chief Accounting Officer & Group Vice President of Fin.
Ms. Madelyn Zeylikman
SVice President, Gen. Counsel & Sec.
Ms. Mei Jang
Senior Vice President of Technical Operations
Mr. Sanj K. Patel
Chief Executive Officer & Chairman
Mr. Eben Tessari
Senior Vice President & Chief Operating Officer
Rachel Frank
Associate Director of Investor Relations
Ms. Melissa Manno
Senior Vice President & Chief HR Officer
Dr. John F. Paolini
Senior Vice President & Chief Medical Officer
Mr. Chad Morin
SVice President, Chief Compliance Officer & Head of Quality
Mr. Mark Ragosa C.F.A.
Senior Vice President & Chief Financial Officer

How KNSA did perform over past 52-week?

KNSA's closing price is 144.92% higher than its 52-week low of $18.26 where as its distance from 52-week high of $45.50 is -1.74%.

How many employees does KNSA have?

Number of KNSA employees currently stands at 315.

Link for KNSA official website?

Official Website of KNSA is: https://www.kiniksa.com

How do I contact KNSA?

KNSA could be contacted at phone 781 439 9100 and can also be accessed through its website. KNSA operates from Clarendon House, Hamilton, HM 11, Bermuda.

How many shares of KNSA are traded daily?

KNSA stock volume for the day was 309.56K shares. The average number of KNSA shares traded daily for last 3 months was 498.24K.

What is the market cap of KNSA currently?

The market value of KNSA currently stands at $3.28B with its latest stock price at $44.71 and 73.29M of its shares outstanding.

Stocks Telegraph provides information and tools designed to assist investors and Wall Street players. A major goal is to offer financiers comprehensive information that will help them gain insight into investing.

Stocks Telegraph does not provide any advice or recommendations for buying or selling stocks, securities, or other financial products. Information contained on this website is for informational purposes only and should not be construed as professional financial, investment or other advice. Stocks Telegraph is not liable for any loss or damage that may occur as a result of reliance on this data.

Employees	315
Beta	0.05
Sales or Revenue	$270.26M
5Y Sales Change%	0%
Fiscal Year Ends	December
Sector	Healthcare
Industry	Biotechnology

KNSA Company Profile and Key Details

Kiniksa Pharmaceuticals

Price Chart

Stock Price Today

Stock Snapshot

Relevant Articles

SEC Fillings

Current Report (8-k)

Annual Report (10-k)

Stock Price History Chart

Contact Details

About Company

Company Information

Stock Peers

Company Overview

Technical Performance

Valuation Metrics

Dividend & Fair Value

Earnings & Analyst Outlook

Shareholding & Insider Activity

Financial & Profitability Overview

Quarterly Financial Highlights

Price Forecast & Outlook

Key Takeaways

Frequently Asked Questions

Shareholding & Insider Activity

Earnings & Analyst Outlook

Dividend & Fair Value

Company Overview

Financial & Profitability Overview

Quarterly Financial Highlights

Valuation Metrics

Key Takeaways

Price Forecast & Outlook